News
Insmed Incorporated (NASDAQ:INSM) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company eyes Brensocatib approval by August 12, and its TPIP Phase 3 and $750 million funding bolsters ...
With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...
PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...
Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to a potential multibillion ...
Stocktwits on MSN2d
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...
Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...
Schwartz covers the Healthcare sector, focusing on stocks such as uniQure, KalVista Pharmaceuticals, and Insmed. According to TipRanks, Schwartz has an average return of 15.6% and a 47.59% success ...
Stocktwits on MSN2d
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic
Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback